Targeted therapy options for targeted therapy for CCA patients with aberrant FGFRs, IDH1/2 genes, namely pemigatinib (FGFR inhibitor) and ivosidenib (mutant IDH inhibitor), which cover only around 10–15% and 15–20% of the iCCA patients [19, 20]. Here, IDH1 is linked to infantile convulsions and choreoathetosis.